ESSA Pharmaceuticals, Inc.

76 articles with ESSA Pharmaceuticals, Inc.

• ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

  8/23/2019

  ESSA Pharma Inc. (NASDAQ: EPIX; TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering").

• ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

  8/14/2019

  ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019

• ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective

  7/31/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics

  7/30/2019

  ESSA Pharma Inc. is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006, pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer

  7/15/2019

  ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer ("CMO"). 

• ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders

  6/26/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders of the Company held on June 25, 2019 in Vancouver, British Columbia, Canada.

• ESSA Provides an Update to the Acquisition of Realm Therapeutics

  6/26/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006.

• Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

  5/16/2019

  ESSA Pharma Inc. announced that it has entered into a definitive agreement with Realm Therapeutics plc setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.

• Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting

  5/4/2019

  ESSA Pharma Inc. presented new preclinical data on ESSA's lead Investigational New Drug candidate at the 2019 American Urological Association Annual Meeting.

• ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019

  4/25/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1 at 10:30am Eastern Standard Time at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.

• ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting

  4/17/2019

  ESSA Pharma Inc. announced an abstract on ESSA's aniten compounds for metastatic castration-resistant prostate cancer has been selected for a moderated poster presentation at the upcoming 2019 American Urological Association Annual Meeting from May 3-6 in Chicago, Illinois.

• ESSA Pharma Grants Stock Options

  4/12/2019

  ESSA Pharma Inc. announced that, pursuant to its stock option plan, it has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation.

• ESSA Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference

  3/18/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Oppenheimer 29th Annual Healthcare Conference on Wednesday March 20 at 3:55pm Eastern Daylight Time at the Westin New York Grand Central in New York City.

• ESSA Pharma to Attend the 31st Annual ROTH Conference

  3/14/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be attending the 31st Annual ROTH Conference to be held on March 17 -19 at the Ritz Carlton Laguna Niguel in Dana Point, California.

• ESSA Pharma Announces Two Abstracts Selected to be Presented at the 2019 Genitourinary Cancers Symposium

  2/11/2019

  ESSA compounds have been selected for a poster presentation at the upcoming 2019 Genitourinary Cancers Symposium to be held February 14 – 16, 2019 at the Moscone Center in San Francisco, CA. 

• ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2018

  2/7/2019

  ESSA Pharma Inc. provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2018.

• ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2018

  12/13/2018

  ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal fourth quarter and year ended September 30, 2018.

• ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors

  10/22/2018

  Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.

• ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018

  8/29/2018

  ESSA Pharma Inc. today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference

• ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018

  8/14/2018

  ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for the treatment of prostate cance